View ValuationChimeric Therapeutics 将来の成長Future 基準チェック /06現在、 Chimeric Therapeuticsの成長と収益を予測するのに十分なアナリストの調査がありません。主要情報n/a収益成長率n/aEPS成長率Biotechs 収益成長34.7%収益成長率n/a将来の株主資本利益率n/aアナリストカバレッジNone最終更新日n/a今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesBoard Change • May 20No independent directorsThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 5 new directors. 6 experienced directors. No highly experienced directors. No independent directors (5 non-independent directors). Non-Executive Director Lesley Cooper is the most experienced director on the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of board continuity. Lack of experienced directors.Board Change • May 01No independent directorsThere are 4 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 4 new directors. 6 experienced directors. No highly experienced directors. No independent directors (5 non-independent directors). Non-Executive Director Lesley Cooper is the most experienced director on the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of experienced directors.Board Change • Dec 24No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. Non-Executive Director Henry Prince was the last director to join the board, commencing their role in 2025. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.お知らせ • Dec 23Chimeric Therapeutics Limited has filed a Follow-on Equity Offering in the amount of AUD 4.4 million.Chimeric Therapeutics Limited has filed a Follow-on Equity Offering in the amount of AUD 4.4 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 776,567,389 Price\Range: AUD 0.003 Discount Per Security: AUD 0.00018 Security Features: Attached Options Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 690,099,278 Price\Range: AUD 0.003 Discount Per Security: AUD 0.00018 Security Features: Attached Options Transaction Features: Subsequent Direct Listingお知らせ • Oct 27Chimeric Therapeutics Limited, Annual General Meeting, Nov 25, 2025Chimeric Therapeutics Limited, Annual General Meeting, Nov 25, 2025. Location: at level 3, 62 lygon street, carlton, victoria 3053, Australiaお知らせ • Oct 10Chimeric Therapeutics Limited has completed a Follow-on Equity Offering in the amount of AUD 6.6 million.Chimeric Therapeutics Limited has completed a Follow-on Equity Offering in the amount of AUD 6.6 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 164,307,917 Price\Range: AUD 0.004 Discount Per Security: AUD 0.00024 Security Features: Attached Options Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 1,092,679,329 Price\Range: AUD 0.004 Discount Per Security: AUD 0.00024 Security Features: Attached Options Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 387,577,500 Price\Range: AUD 0.004 Discount Per Security: AUD 0.00024 Security Features: Attached Options Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 5,435,254 Price\Range: AUD 0.004 Discount Per Security: AUD 0.00024 Transaction Features: Subsequent Direct ListingBoard Change • Aug 18No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 5 non-independent directors. Non-Executive Director H. Prince was the last director to join the board, commencing their role in 2025. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.お知らせ • May 20Chimeric Therapeutics Limited has filed a Follow-on Equity Offering in the amount of AUD 6.6 million.Chimeric Therapeutics Limited has filed a Follow-on Equity Offering in the amount of AUD 6.6 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 164,300,000 Price\Range: AUD 0.004 Discount Per Security: AUD 0.00024 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 1,485,700,000 Price\Range: AUD 0.004 Discount Per Security: AUD 0.00024 Security Features: Attached Options Transaction Features: Subsequent Direct Listingお知らせ • Apr 24Chimeric Therapeutics Limited has completed a Follow-on Equity Offering in the amount of AUD 0.986015 million.Chimeric Therapeutics Limited has completed a Follow-on Equity Offering in the amount of AUD 0.986015 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 197,203,052 Price\Range: AUD 0.005 Discount Per Security: AUD 0.0001 Transaction Features: Rights Offeringお知らせ • Mar 04Chimeric Therapeutics Limited has filed a Follow-on Equity Offering in the amount of AUD 3.1903 million.Chimeric Therapeutics Limited has filed a Follow-on Equity Offering in the amount of AUD 3.1903 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 638,059,938 Price\Range: AUD 0.005 Discount Per Security: AUD 0.0003 Transaction Features: Rights Offeringお知らせ • Feb 13Chimeric Therapeutics Limited has completed a Follow-on Equity Offering in the amount of AUD 0.1 million.Chimeric Therapeutics Limited has completed a Follow-on Equity Offering in the amount of AUD 0.1 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 20,000,000 Price\Range: AUD 0.005 Transaction Features: Subsequent Direct ListingBoard Change • Feb 04No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. Non-Executive Director Eric Sullivan was the last director to join the board, commencing their role in 2023. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.Board Change • Dec 24No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. Non-Executive Director Eric Sullivan was the last director to join the board, commencing their role in 2023. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.お知らせ • Dec 09Chimeric Therapeutics Limited has completed a Follow-on Equity Offering in the amount of AUD 5 million.Chimeric Therapeutics Limited has completed a Follow-on Equity Offering in the amount of AUD 5 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 69,990,973 Price\Range: AUD 0.008 Discount Per Security: AUD 0.00048 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 430,009,027 Price\Range: AUD 0.008 Discount Per Security: AUD 0.00048 Security Features: Attached Options Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 125,000,000 Price\Range: AUD 0.008 Discount Per Security: AUD 0.00048 Transaction Features: Subsequent Direct Listingお知らせ • Oct 23Chimeric Therapeutics Limited has filed a Follow-on Equity Offering in the amount of AUD 5 million.Chimeric Therapeutics Limited has filed a Follow-on Equity Offering in the amount of AUD 5 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 69,990,973 Price\Range: AUD 0.008 Discount Per Security: AUD 0.00048 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 430,009,027 Price\Range: AUD 0.008 Discount Per Security: AUD 0.00048 Security Features: Attached Options Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 125,000,000 Price\Range: AUD 0.008 Discount Per Security: AUD 0.00048 Transaction Features: Subsequent Direct Listingお知らせ • Oct 14Chimeric Therapeutics Limited, Annual General Meeting, Nov 12, 2024Chimeric Therapeutics Limited, Annual General Meeting, Nov 12, 2024. Location: at level 3, 62 lygon street, carlton, victoria 3053 AustraliaNew Risk • Sep 10New minor risk - Revenue sizeThe company makes less than US$5m in revenue. Total revenue: AU$7.5m (US$5.0m) This is considered a minor risk. Companies with a small amount of revenue are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$7.5m free cash flow). Earnings have declined by 9.2% per year over the past 5 years. Shareholders have been substantially diluted in the past year (69% increase in shares outstanding). Market cap is less than US$10m (AU$13.4m market cap, or US$8.93m). Minor Risks Currently unprofitable and not forecast to become profitable next year (AU$21m net loss next year). Share price has been volatile over the past 3 months (14% average weekly change). Revenue is less than US$5m (AU$7.5m revenue, or US$5.0m).New Risk • Jun 05New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: AU$14.7m (US$9.74m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Earnings are forecast to decline by an average of 42% per year for the foreseeable future. Shareholders have been substantially diluted in the past year (97% increase in shares outstanding). Market cap is less than US$10m (AU$14.7m market cap, or US$9.74m). Minor Risk Currently unprofitable and not forecast to become profitable next year (AU$17m net loss next year).New Risk • May 29New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Australian stocks, typically moving 13% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Earnings are forecast to decline by an average of 42% per year for the foreseeable future. Shareholders have been substantially diluted in the past year (96% increase in shares outstanding). Minor Risks Currently unprofitable and not forecast to become profitable next year (AU$17m net loss next year). Share price has been volatile over the past 3 months (13% average weekly change). Market cap is less than US$100m (AU$17.1m market cap, or US$11.4m).New Risk • Mar 01New major risk - Revenue and earnings growthEarnings have declined by 20% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 20% per year over the past 5 years. Shareholders have been substantially diluted in the past year (101% increase in shares outstanding). Minor Risk Market cap is less than US$100m (AU$21.9m market cap, or US$14.3m).お知らせ • Jan 18Chimeric Therapeutics Limited has completed a Follow-on Equity Offering in the amount of AUD 7.664077 million.Chimeric Therapeutics Limited has completed a Follow-on Equity Offering in the amount of AUD 7.664077 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 273,717,042 Price\Range: AUD 0.028 Transaction Features: Rights OfferingNew Risk • Dec 13New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 63% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (18% average weekly change). Share price has been highly volatile over the past 3 months (18% average weekly change). Shareholders have been substantially diluted in the past year (63% increase in shares outstanding). Minor Risks Revenue is less than US$5m (AU$4.5m revenue, or US$3.0m). Revenue is less than US$5m (AU$4.5m revenue, or US$3.0m). Market cap is less than US$100m (AU$19.9m market cap, or US$13.1m). Market cap is less than US$100m (AU$19.9m market cap, or US$13.1m).お知らせ • Nov 01Chimeric Therapeutics Announces FDA Clearance of IND Application for CHM 2101Chimeric Therapeutics announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application of CHM 2101, Chimeric's first in class CDH17 CAR T cell therapy for gastrointestinal cancers. The company plans to investigate CHM 2101 in a multi center, open label Phase 1A/B clinical trial for patients with advanced Colorectal Cancer, Gastric Cancer and Neuroendocrine Tumours. CHM 2101 is a 3rd generation, novel CDH 17 CAR T cell therapy that targets CDH17, a cancer target associated with poor prognosis and metastasis in the most common gastrointestinal tumors including Colorectal Cancer, gastric Cancer and Neuroendocrine Tumours. These experiments demonstrated that CHM 2101 was able to eradicate established tumours in seven cancer models with no toxicity to normal tissues. With the FDA IND clearance Chimeric will now begin the initiation of a phase 1/2 multi-site clinical trial in patients with advanced ColorectAL Cancer, Gastric Cancer and neuroendocrine Tumours. The study is planned to begin patient enrollment in 2024.New Risk • Oct 23New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Australian stocks, typically moving 17% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$16m free cash flow). Share price has been highly volatile over the past 3 months (17% average weekly change). Minor Risks Shareholders have been diluted in the past year (26% increase in shares outstanding). Revenue is less than US$5m (AU$4.5m revenue, or US$2.8m). Market cap is less than US$100m (AU$19.8m market cap, or US$12.5m).お知らせ • Oct 16Chimeric Therapeutics Limited, Annual General Meeting, Nov 14, 2023Chimeric Therapeutics Limited, Annual General Meeting, Nov 14, 2023, at 11:01 AUS Eastern Standard Time. Location: Level 3, 62 Lygon Street, Carlton Victoria Australia Agenda: To consider and receive the financial report, the Directors' report and the auditor's report for the year ended 30 June 2023; to consider the Remuneration Report; to consider Election of Director Mr Phillip Hains; to consider Election of Director Mr Eric Sullivan; to consider and Approval of 10% capacity under Listing Rule 7.1A; to consider the Renewal of Omnibus Incentive Plan; to consider Approval to issue Incentive Options to Director Mr Eric Sullivan; to consider Ratification of agreement to issue Shares to Lind Global Fund II LP; to consider Amendment to Constitution; and to consider other matters.New Risk • Aug 31New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2022. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$20m free cash flow). Earnings are forecast to decline by an average of 31% per year for the foreseeable future. Minor Risks Latest financial reports are more than 6 months old (reported December 2022 fiscal period end). Currently unprofitable and not forecast to become profitable over next 3 years (AU$49m net loss in 3 years). Share price has been volatile over the past 3 months (13% average weekly change). Shareholders have been diluted in the past year (24% increase in shares outstanding). Revenue is less than US$5m (AU$5.7m revenue, or US$3.7m). Market cap is less than US$100m (AU$19.6m market cap, or US$12.7m).お知らせ • Aug 30Chimeric Therapeutics Limited Announces Board ChangesChimeric Therapeutics announced the appointment of Mr. Eric Sullivan as a Non-Executive Director, effective 30 August 2023. Mr. Sullivan is a senior finance and operations leader with a focus on private-to-public biotechnology company building, strategy, fundraising and financial planning. He brings with him an impressive background in the biotechnology sector, having served in senior finance and operations leadership roles across a number of high-growth public biotech companies, including bluebird bio, Merrimack Pharmaceuticals and TCR2 Therapeutics. Additionally, his experience with blue-chip private companies, such as Oncorus, Gemini Therapeutics, and Triplet Therapeutics, further underpins his expertise in financial planning, fundraising, board management and investor relations. Mr. Sullivan replaces the outgoing Ms Cindy Elkins, who is stepping down from the Chimeric Board of Directors.お知らせ • Aug 03Chimeric Therapeutics Limited Announces the Resignation of George Matcham as Non-Executive DirectorChimeric Therapeutics Limited announced that George Matcham has resigned as a Non-Executive Director, effective 3 August 2023. George has served on the Chimeric Board since July 2021 and has provided valued contributions to the Company.お知らせ • Jul 12Chimeric Therapeutics Limited Announces Board ChangesChimeric Therapeutics announces that Ms Leslie Chong has resigned from her position as Non-Executive Director to focus on her duties as Chief Executive Officer of Imugene Limited.Leslie has served on the Chimeric Board since August 2020 and has provided valued contributions and experienced counsel to the Company. Following the resignation, the Board has appointed Phillip Hains to fill a casual vacancy. Phillip is the Company's CFO and Joint Company Secretary and Principal of Melbourne based "The CFO Solution".お知らせ • Jun 05Chimeric Therapeutics Limited Announces Launch of New Phase 1B Glioblastoma Clinical TrialChimeric Therapeutics announced activation of a Phase 1B clinical trial in patients with recurrent and/or progressive glioblastoma multiforme (GBM) to assess the safety and efficacy of CHM 1101, the company's first in class CLTX CAR T cell therapy. The trial is now open for enrollment at the Sarah Cannon Transplant & Cellular Therapy Program at St. David's South Austin Medical Center in Austin, Texas. This Phase 1B trial, being conducted under a US IND, is a two-part clinical trial designed to determine a recommended Phase 2 dose and administration schedule. Part A of the trial will enroll 3-6 patients at the highest dose tested in the ongoing clinical trial at City of Hope Cancer Centre. In late 2023, Chimeric will assess the clinical safety and activity from the CHM 1101 clinical program. Based on a favorable review of the results of that assessment, Part B of the trial, a dose expansion cohort, will be opened to enroll 12 to 26 additional patients. Upon successful completion of the Part B dose expansion cohort, the Company intends to design and initiate a registration trial, in collaboration with global regulatory feedback. CHM 1101 (CLTX CAR T) is a first-in-class CAR T therapy that has the potential to address the high unmet medical need of patients with recurrent or progressive glioblastoma. Research to develop the intellectual property covering this CAR T cell therapy took place at City of Hope. CHM 1101 cells uniquely utilize chlorotoxin (CLTX), a peptide component of scorpion venom, as the tumor-targeting component of the chimeric antigen receptor (CAR). CHM 1101 CAR T cells have been shown in preclinical models to bind more broadly and specifically to GBM cells than other targeting domains like EGFR, HER-2 or IL-13. In preclinical models, CHM 1101 cells also demonstrated potent antitumor activity against glioblastoma while not exhibiting any off-tumor recognition of normal human cells and tissues, indicating a potentially optimal safety and efficacy profile. CHM 1101 is currently being studied in a Phase 1B clinical trial in recurrent /progressive glioblastoma. Initial positive data from the investigator-initiated Phase 1A trial has been presented on patients treated in the first two dose levels of the trial.Board Change • Mar 23No independent directorsThere are 8 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 8 new directors. 4 experienced directors. No highly experienced directors. No independent directors (6 non-independent directors). Founder & Executive Chairman Paul Hopper is the most experienced director on the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of board continuity. Lack of experienced directors. このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、Chimeric Therapeutics は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。 シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。 業績と収益の成長予測CHIA:CHM - アナリストの将来予測と過去の財務データ ( )AUD Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数12/31/202510-19-8-8N/A9/30/202511-15-8-8N/A6/30/202513-10-7-7N/A3/31/20257-14-6-6N/A12/31/20242-18-5-5N/A9/30/20245-15-7-7N/A6/30/20247-13-8-8N/A3/31/202410-12-8-8N/A12/31/202312-12-8-8N/A9/30/20238-19-12-12N/A6/30/20235-26-16-16N/A3/31/20235-22-18-18N/A12/31/20226-18-20-20N/A9/30/20224-17-17-16N/A6/30/20223-16-14-13N/A3/31/20221-19-15-13N/A12/31/2021N/A-21-16-13N/A9/30/2021N/A-18-15-11N/A6/30/2021N/A-15-14-9N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: CHMの予測収益成長が 貯蓄率 ( 3.8% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: CHMの収益がAustralian市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: CHMの収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: CHMの収益がAustralian市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。高い収益成長: CHMの収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。一株当たり利益成長率予想将来の株主資本利益率将来のROE: CHMの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/08/15 07:38終値2026/08/14 00:00収益2025/12/31年間収益2025/06/30データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Chimeric Therapeutics Limited 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。3 アナリスト機関Hunter DiamondDiamond Equity Research LLCMaxim JacobsEdison Investment Researchnull nullLodge Partners Pty Ltd.
Board Change • May 20No independent directorsThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 5 new directors. 6 experienced directors. No highly experienced directors. No independent directors (5 non-independent directors). Non-Executive Director Lesley Cooper is the most experienced director on the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of board continuity. Lack of experienced directors.
Board Change • May 01No independent directorsThere are 4 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 4 new directors. 6 experienced directors. No highly experienced directors. No independent directors (5 non-independent directors). Non-Executive Director Lesley Cooper is the most experienced director on the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of experienced directors.
Board Change • Dec 24No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. Non-Executive Director Henry Prince was the last director to join the board, commencing their role in 2025. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
お知らせ • Dec 23Chimeric Therapeutics Limited has filed a Follow-on Equity Offering in the amount of AUD 4.4 million.Chimeric Therapeutics Limited has filed a Follow-on Equity Offering in the amount of AUD 4.4 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 776,567,389 Price\Range: AUD 0.003 Discount Per Security: AUD 0.00018 Security Features: Attached Options Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 690,099,278 Price\Range: AUD 0.003 Discount Per Security: AUD 0.00018 Security Features: Attached Options Transaction Features: Subsequent Direct Listing
お知らせ • Oct 27Chimeric Therapeutics Limited, Annual General Meeting, Nov 25, 2025Chimeric Therapeutics Limited, Annual General Meeting, Nov 25, 2025. Location: at level 3, 62 lygon street, carlton, victoria 3053, Australia
お知らせ • Oct 10Chimeric Therapeutics Limited has completed a Follow-on Equity Offering in the amount of AUD 6.6 million.Chimeric Therapeutics Limited has completed a Follow-on Equity Offering in the amount of AUD 6.6 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 164,307,917 Price\Range: AUD 0.004 Discount Per Security: AUD 0.00024 Security Features: Attached Options Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 1,092,679,329 Price\Range: AUD 0.004 Discount Per Security: AUD 0.00024 Security Features: Attached Options Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 387,577,500 Price\Range: AUD 0.004 Discount Per Security: AUD 0.00024 Security Features: Attached Options Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 5,435,254 Price\Range: AUD 0.004 Discount Per Security: AUD 0.00024 Transaction Features: Subsequent Direct Listing
Board Change • Aug 18No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 5 non-independent directors. Non-Executive Director H. Prince was the last director to join the board, commencing their role in 2025. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
お知らせ • May 20Chimeric Therapeutics Limited has filed a Follow-on Equity Offering in the amount of AUD 6.6 million.Chimeric Therapeutics Limited has filed a Follow-on Equity Offering in the amount of AUD 6.6 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 164,300,000 Price\Range: AUD 0.004 Discount Per Security: AUD 0.00024 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 1,485,700,000 Price\Range: AUD 0.004 Discount Per Security: AUD 0.00024 Security Features: Attached Options Transaction Features: Subsequent Direct Listing
お知らせ • Apr 24Chimeric Therapeutics Limited has completed a Follow-on Equity Offering in the amount of AUD 0.986015 million.Chimeric Therapeutics Limited has completed a Follow-on Equity Offering in the amount of AUD 0.986015 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 197,203,052 Price\Range: AUD 0.005 Discount Per Security: AUD 0.0001 Transaction Features: Rights Offering
お知らせ • Mar 04Chimeric Therapeutics Limited has filed a Follow-on Equity Offering in the amount of AUD 3.1903 million.Chimeric Therapeutics Limited has filed a Follow-on Equity Offering in the amount of AUD 3.1903 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 638,059,938 Price\Range: AUD 0.005 Discount Per Security: AUD 0.0003 Transaction Features: Rights Offering
お知らせ • Feb 13Chimeric Therapeutics Limited has completed a Follow-on Equity Offering in the amount of AUD 0.1 million.Chimeric Therapeutics Limited has completed a Follow-on Equity Offering in the amount of AUD 0.1 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 20,000,000 Price\Range: AUD 0.005 Transaction Features: Subsequent Direct Listing
Board Change • Feb 04No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. Non-Executive Director Eric Sullivan was the last director to join the board, commencing their role in 2023. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
Board Change • Dec 24No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. Non-Executive Director Eric Sullivan was the last director to join the board, commencing their role in 2023. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
お知らせ • Dec 09Chimeric Therapeutics Limited has completed a Follow-on Equity Offering in the amount of AUD 5 million.Chimeric Therapeutics Limited has completed a Follow-on Equity Offering in the amount of AUD 5 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 69,990,973 Price\Range: AUD 0.008 Discount Per Security: AUD 0.00048 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 430,009,027 Price\Range: AUD 0.008 Discount Per Security: AUD 0.00048 Security Features: Attached Options Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 125,000,000 Price\Range: AUD 0.008 Discount Per Security: AUD 0.00048 Transaction Features: Subsequent Direct Listing
お知らせ • Oct 23Chimeric Therapeutics Limited has filed a Follow-on Equity Offering in the amount of AUD 5 million.Chimeric Therapeutics Limited has filed a Follow-on Equity Offering in the amount of AUD 5 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 69,990,973 Price\Range: AUD 0.008 Discount Per Security: AUD 0.00048 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 430,009,027 Price\Range: AUD 0.008 Discount Per Security: AUD 0.00048 Security Features: Attached Options Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 125,000,000 Price\Range: AUD 0.008 Discount Per Security: AUD 0.00048 Transaction Features: Subsequent Direct Listing
お知らせ • Oct 14Chimeric Therapeutics Limited, Annual General Meeting, Nov 12, 2024Chimeric Therapeutics Limited, Annual General Meeting, Nov 12, 2024. Location: at level 3, 62 lygon street, carlton, victoria 3053 Australia
New Risk • Sep 10New minor risk - Revenue sizeThe company makes less than US$5m in revenue. Total revenue: AU$7.5m (US$5.0m) This is considered a minor risk. Companies with a small amount of revenue are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$7.5m free cash flow). Earnings have declined by 9.2% per year over the past 5 years. Shareholders have been substantially diluted in the past year (69% increase in shares outstanding). Market cap is less than US$10m (AU$13.4m market cap, or US$8.93m). Minor Risks Currently unprofitable and not forecast to become profitable next year (AU$21m net loss next year). Share price has been volatile over the past 3 months (14% average weekly change). Revenue is less than US$5m (AU$7.5m revenue, or US$5.0m).
New Risk • Jun 05New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: AU$14.7m (US$9.74m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Earnings are forecast to decline by an average of 42% per year for the foreseeable future. Shareholders have been substantially diluted in the past year (97% increase in shares outstanding). Market cap is less than US$10m (AU$14.7m market cap, or US$9.74m). Minor Risk Currently unprofitable and not forecast to become profitable next year (AU$17m net loss next year).
New Risk • May 29New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Australian stocks, typically moving 13% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Earnings are forecast to decline by an average of 42% per year for the foreseeable future. Shareholders have been substantially diluted in the past year (96% increase in shares outstanding). Minor Risks Currently unprofitable and not forecast to become profitable next year (AU$17m net loss next year). Share price has been volatile over the past 3 months (13% average weekly change). Market cap is less than US$100m (AU$17.1m market cap, or US$11.4m).
New Risk • Mar 01New major risk - Revenue and earnings growthEarnings have declined by 20% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 20% per year over the past 5 years. Shareholders have been substantially diluted in the past year (101% increase in shares outstanding). Minor Risk Market cap is less than US$100m (AU$21.9m market cap, or US$14.3m).
お知らせ • Jan 18Chimeric Therapeutics Limited has completed a Follow-on Equity Offering in the amount of AUD 7.664077 million.Chimeric Therapeutics Limited has completed a Follow-on Equity Offering in the amount of AUD 7.664077 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 273,717,042 Price\Range: AUD 0.028 Transaction Features: Rights Offering
New Risk • Dec 13New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 63% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (18% average weekly change). Share price has been highly volatile over the past 3 months (18% average weekly change). Shareholders have been substantially diluted in the past year (63% increase in shares outstanding). Minor Risks Revenue is less than US$5m (AU$4.5m revenue, or US$3.0m). Revenue is less than US$5m (AU$4.5m revenue, or US$3.0m). Market cap is less than US$100m (AU$19.9m market cap, or US$13.1m). Market cap is less than US$100m (AU$19.9m market cap, or US$13.1m).
お知らせ • Nov 01Chimeric Therapeutics Announces FDA Clearance of IND Application for CHM 2101Chimeric Therapeutics announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application of CHM 2101, Chimeric's first in class CDH17 CAR T cell therapy for gastrointestinal cancers. The company plans to investigate CHM 2101 in a multi center, open label Phase 1A/B clinical trial for patients with advanced Colorectal Cancer, Gastric Cancer and Neuroendocrine Tumours. CHM 2101 is a 3rd generation, novel CDH 17 CAR T cell therapy that targets CDH17, a cancer target associated with poor prognosis and metastasis in the most common gastrointestinal tumors including Colorectal Cancer, gastric Cancer and Neuroendocrine Tumours. These experiments demonstrated that CHM 2101 was able to eradicate established tumours in seven cancer models with no toxicity to normal tissues. With the FDA IND clearance Chimeric will now begin the initiation of a phase 1/2 multi-site clinical trial in patients with advanced ColorectAL Cancer, Gastric Cancer and neuroendocrine Tumours. The study is planned to begin patient enrollment in 2024.
New Risk • Oct 23New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Australian stocks, typically moving 17% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$16m free cash flow). Share price has been highly volatile over the past 3 months (17% average weekly change). Minor Risks Shareholders have been diluted in the past year (26% increase in shares outstanding). Revenue is less than US$5m (AU$4.5m revenue, or US$2.8m). Market cap is less than US$100m (AU$19.8m market cap, or US$12.5m).
お知らせ • Oct 16Chimeric Therapeutics Limited, Annual General Meeting, Nov 14, 2023Chimeric Therapeutics Limited, Annual General Meeting, Nov 14, 2023, at 11:01 AUS Eastern Standard Time. Location: Level 3, 62 Lygon Street, Carlton Victoria Australia Agenda: To consider and receive the financial report, the Directors' report and the auditor's report for the year ended 30 June 2023; to consider the Remuneration Report; to consider Election of Director Mr Phillip Hains; to consider Election of Director Mr Eric Sullivan; to consider and Approval of 10% capacity under Listing Rule 7.1A; to consider the Renewal of Omnibus Incentive Plan; to consider Approval to issue Incentive Options to Director Mr Eric Sullivan; to consider Ratification of agreement to issue Shares to Lind Global Fund II LP; to consider Amendment to Constitution; and to consider other matters.
New Risk • Aug 31New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2022. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$20m free cash flow). Earnings are forecast to decline by an average of 31% per year for the foreseeable future. Minor Risks Latest financial reports are more than 6 months old (reported December 2022 fiscal period end). Currently unprofitable and not forecast to become profitable over next 3 years (AU$49m net loss in 3 years). Share price has been volatile over the past 3 months (13% average weekly change). Shareholders have been diluted in the past year (24% increase in shares outstanding). Revenue is less than US$5m (AU$5.7m revenue, or US$3.7m). Market cap is less than US$100m (AU$19.6m market cap, or US$12.7m).
お知らせ • Aug 30Chimeric Therapeutics Limited Announces Board ChangesChimeric Therapeutics announced the appointment of Mr. Eric Sullivan as a Non-Executive Director, effective 30 August 2023. Mr. Sullivan is a senior finance and operations leader with a focus on private-to-public biotechnology company building, strategy, fundraising and financial planning. He brings with him an impressive background in the biotechnology sector, having served in senior finance and operations leadership roles across a number of high-growth public biotech companies, including bluebird bio, Merrimack Pharmaceuticals and TCR2 Therapeutics. Additionally, his experience with blue-chip private companies, such as Oncorus, Gemini Therapeutics, and Triplet Therapeutics, further underpins his expertise in financial planning, fundraising, board management and investor relations. Mr. Sullivan replaces the outgoing Ms Cindy Elkins, who is stepping down from the Chimeric Board of Directors.
お知らせ • Aug 03Chimeric Therapeutics Limited Announces the Resignation of George Matcham as Non-Executive DirectorChimeric Therapeutics Limited announced that George Matcham has resigned as a Non-Executive Director, effective 3 August 2023. George has served on the Chimeric Board since July 2021 and has provided valued contributions to the Company.
お知らせ • Jul 12Chimeric Therapeutics Limited Announces Board ChangesChimeric Therapeutics announces that Ms Leslie Chong has resigned from her position as Non-Executive Director to focus on her duties as Chief Executive Officer of Imugene Limited.Leslie has served on the Chimeric Board since August 2020 and has provided valued contributions and experienced counsel to the Company. Following the resignation, the Board has appointed Phillip Hains to fill a casual vacancy. Phillip is the Company's CFO and Joint Company Secretary and Principal of Melbourne based "The CFO Solution".
お知らせ • Jun 05Chimeric Therapeutics Limited Announces Launch of New Phase 1B Glioblastoma Clinical TrialChimeric Therapeutics announced activation of a Phase 1B clinical trial in patients with recurrent and/or progressive glioblastoma multiforme (GBM) to assess the safety and efficacy of CHM 1101, the company's first in class CLTX CAR T cell therapy. The trial is now open for enrollment at the Sarah Cannon Transplant & Cellular Therapy Program at St. David's South Austin Medical Center in Austin, Texas. This Phase 1B trial, being conducted under a US IND, is a two-part clinical trial designed to determine a recommended Phase 2 dose and administration schedule. Part A of the trial will enroll 3-6 patients at the highest dose tested in the ongoing clinical trial at City of Hope Cancer Centre. In late 2023, Chimeric will assess the clinical safety and activity from the CHM 1101 clinical program. Based on a favorable review of the results of that assessment, Part B of the trial, a dose expansion cohort, will be opened to enroll 12 to 26 additional patients. Upon successful completion of the Part B dose expansion cohort, the Company intends to design and initiate a registration trial, in collaboration with global regulatory feedback. CHM 1101 (CLTX CAR T) is a first-in-class CAR T therapy that has the potential to address the high unmet medical need of patients with recurrent or progressive glioblastoma. Research to develop the intellectual property covering this CAR T cell therapy took place at City of Hope. CHM 1101 cells uniquely utilize chlorotoxin (CLTX), a peptide component of scorpion venom, as the tumor-targeting component of the chimeric antigen receptor (CAR). CHM 1101 CAR T cells have been shown in preclinical models to bind more broadly and specifically to GBM cells than other targeting domains like EGFR, HER-2 or IL-13. In preclinical models, CHM 1101 cells also demonstrated potent antitumor activity against glioblastoma while not exhibiting any off-tumor recognition of normal human cells and tissues, indicating a potentially optimal safety and efficacy profile. CHM 1101 is currently being studied in a Phase 1B clinical trial in recurrent /progressive glioblastoma. Initial positive data from the investigator-initiated Phase 1A trial has been presented on patients treated in the first two dose levels of the trial.
Board Change • Mar 23No independent directorsThere are 8 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 8 new directors. 4 experienced directors. No highly experienced directors. No independent directors (6 non-independent directors). Founder & Executive Chairman Paul Hopper is the most experienced director on the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of board continuity. Lack of experienced directors.